Wegovy 1.7 mg/0.75 mL pre-filled pen-injector

Wegovy 1.7 mg/0.75 mL pre-filled pen-injector

 Wegovy® (semaglutide) is a prescription medication used for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia. It is a GLP-1 receptor agonist that helps patients lose weight by reducing appetite and improving insulin sensitivity. Wegovy is prescribed in combination with a reduced-calorie diet and increased physical activity.

The 1.7 mg/0.75 mL pre-filled pen-injector is an important step in the dose escalation process, typically used after the 1 mg dose. This allows patients to continue increasing their dose toward the 2.4 mg maintenance dose, based on their treatment progress and tolerance.

How It Works:
Semaglutide, the active ingredient in Wegovy, is a GLP-1 (glucagon-like peptide-1) receptor agonist. It works by mimicking the effects of GLP-1, a naturally occurring hormone that helps regulate blood sugar levels and appetite. Semaglutide stimulates insulin release in response to meals, inhibits glucagon secretion, and slows gastric emptying. Together, these actions help patients feel fuller, eat less, and manage their weight more effectively.

Dosage and Administration:
Each pre-filled pen contains 1.7 mg of semaglutide in 0.75 mL of solution, which is delivered through a subcutaneous injection once a week. The injection should be administered into the abdomen, thigh, or upper arm. As with previous doses, patients should rotate injection sites to avoid irritation. The 1.7 mg dose is typically used after the 1 mg dose and is a continuation of the gradual titration process toward the 2.4 mg maintenance dose.

Storage Instructions:
Wegovy should be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) before first use. After the first use, the pen can be stored at room temperature (up to 86°F or 30°C) for up to 28 days. Do not freeze the pen, and avoid exposing it to direct heat or sunlight.

Important Safety Information:
Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also not suitable for people with type 1 diabetes or diabetic ketoacidosis.

Common side effects include nausea, diarrhea, constipation, vomiting, abdominal pain, and reduced appetite. Serious but rare risks include pancreatitis, gallbladder disease, and kidney problems. Patients should be regularly monitored for any potential complications.

Clinical Use:
The 1.7 mg dose is a crucial part of the dose escalation regimen for patients using Wegovy. The slow increase in dosage helps minimize gastrointestinal side effects and improves patient adherence to the treatment plan. The ultimate goal is to reach the 2.4 mg maintenance dose for optimal weight loss benefits.